In the last several sessions, International Stem Cell Corp. (OTC:ISCO) stock looks like it could stop its lasting downtrend. The latest news from the company has been its quarter report for the period ending September 2011, which however, does not suggest a stop of the downtrend. 
Yesterday, ISCO closed the market again with a 3.33% increase in the share price at $0.62, while the trading volume was above the average with over 213,000 traded shares. ISCO share price has slipped down from over $2 at the beginning of the year to its present level, and shortly after the company filed its latest financials the stock price fell down to a new 52-week bottom at $0.55.
The quarter report came out in the middle of the month and it does not contain a lot of positive information apart from the 141% increase in the revenue for the three months ended September 2011 as compared to the same period last year. According to the report, the higher revenues came at the cost of higher expenses and the company has still not made any profit from its operations.
ISCO currently derives revenues from its Lifeline Skin Care subsidiary which manufactures cosmetic skin care product developed on the basis of the company’s human stem cell technologies. Though, these revenues have been limited so far and cannot be considered predictable and thus ISCO still has to raise capital from outside to cover its operations.
In addition, the company has outstanding convertible preferred stock and warrants, which also increases the dilution risk and may lead to ISCO lose even more from its market value.
